




Longstanding Access Platforms for Health Technologies: Vaccines, Diagnostics, Therapeutics





### **New priorities**

#### **Contribution to Access**

Strengthening Regional Innovation & Manufacturing



Promoting regional production and innovation is essential to improve health security and reduce global supply chain vulnerabilities

Establishing Regional Supply Agreements for Rapid Response



Enhance preparedness and response capacities through early access to Medical Counter Measures

Creating a Regional Stockpile/Hub



Alleviating supply chain disruptions in emergencies and reducing transportation costs



### **Actions Approved to Address New Priorities**

## of the Capital Accounts

Use of up to 15% of the Capital Accounts only after all credit line requests from countries are secured

- Prepayments, volume guarantees, and innovative financing instruments to incentivize regional manufacturers or regional supply agreements for rapid response.
- Prepayments for the creation of a Hub or Regional stockpile for critical products in crises

# Flexible Contributions to the Capital

Accounts

2.5% Capital Account Contribution exemption on Products from Regional Manufacturers

and promote self-reliance

2.5% Capital Account Contribution exception for large volumes of high-cost products

 Attracting countries with bigger volumes to generate economies of scale. The proposed exemptions benefit all Member States regardless of their income or size.

More **competitive prices** for Member States (MS) from

regional manufacturers to stimulate Local Production



### **Implementing Actions**



The Line of Credit will be the priority



Aligned with mandate and priorities



**Beneficial to all Member States** 



To be implemented in procurement processes & tools



